The 5-Second Trick For Z-LEHD-fmk
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research To guage various intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Key demo aims were To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis patients, when one